The Cancer Genome Atlas and the Development of Personalized Therapy

Friday, October 11, 2013

Clinical trial design for new cancer therapies has historically been focused on a tumor’s tissue of origin, but a Memorial Sloan Kettering paper published on September 26 in Nature Genetics analyzes initial findings from The Cancer Genome Atlas and supports a new approach: one based on the genomic signature of a tumor rather than its tissue of origin.

Memorial Sloan Kettering’s Chair of Computational Biology, Chris Sander, is available to discuss the Nature Genetics study, how the findings may impact current and future treatments, and The Cancer Genome Atlas project.


For more information and to set up an interview, contact the Media Staff.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.